Trade-Ideas LLC identified Vericel ( VCEL) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Vericel as such a stock due to the following factors:

  • VCEL has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $16.6 million.
  • VCEL has traded 267,108 shares today.
  • VCEL is down 4.1% today.
  • VCEL was up 15.6% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in VCEL with the Ticky from Trade-Ideas. See the FREE profile for VCEL NOW at Trade-Ideas

More details on VCEL:

Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. Currently there are 2 analysts that rate Vericel a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Vericel has been 991,900 shares per day over the past 30 days. Vericel has a market cap of $128.1 million and is part of the health care sector and drugs industry. The stock has a beta of 0.14 and a short float of 0.3% with 0.50 days to cover. Shares are up 103.9% year-to-date as of the close of trading on Wednesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates Vericel as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity.

Highlights from the ratings report include:
  • Current return on equity is lower than its ROE from the same quarter one year prior. This is a clear sign of weakness within the company. Compared to other companies in the Biotechnology industry and the overall market, VERICEL CORP's return on equity significantly trails that of both the industry average and the S&P 500.
  • 48.17% is the gross profit margin for VERICEL CORP which we consider to be strong. It has increased significantly from the same period last year. Regardless of the strong results of the gross profit margin, the net profit margin of -39.04% is in-line with the industry average.
  • Net operating cash flow has significantly increased by 91.47% to -$0.72 million when compared to the same quarter last year. In addition, VERICEL CORP has also vastly surpassed the industry average cash flow growth rate of 26.56%.
  • VCEL's debt-to-equity ratio is very low at 0.00 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with this, the company maintains a quick ratio of 2.85, which clearly demonstrates the ability to cover short-term cash needs.
  • This stock has increased by 43.71% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the future course of this stock, we feel that the risks involved in investing in VCEL do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.